Rivastigmine: In Parkinson's disease dementia

CNS Drugs

Volumn 20, Issue 9, 2006, Pages 739-747

  Siddiqui, M Asif A ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

BRADYKINESIA; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; DEMENTIA; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSTONIA; HALLUCINATION; HUMAN; MUSCLE RIGIDITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TREMOR; VOMITING;

ANIMALS; CHOLINESTERASE INHIBITORS; DEMENTIA; DRUG EVALUATION; HUMANS; PARKINSON DISEASE; PHENYLCARBAMATES;

EID: 33748523002     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620090-00003     Document Type: Review

References (31)

1. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 2; 66 (7): 996-1002
2. Levy G, Schupf N, Tang MX, et al. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 2002; 51 (6): 722-9
3. Camicioli R, Fisher N. Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies. Can J Neurol Sci 2004; 31 (1): 7-21
4. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Mov Disord 2003 Sep; 18 Suppl. 6: S72-9
5. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001 Mar; 56 (6): 730-6
6. Williams-Gray CH, Foltynie T, Lewis SJG, et al. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 2006; 20 (6): 477-505
7. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003 Mar; 60 (3): 387-92
8. Braak H, Rub U, Jansen Steur EN, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005 Apr 26; 64 (8): 1404-10
9. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003 Dec; 60 (12): 1745-8
10. Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985 May; 48 (5): 413-21
11. Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002 Apr; 110 (4): 627-39
12. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005 Nov; 102 (47): 17213-8
13. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003 Jun 10; 60 (11): 1852-3
14. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998 Nov; 13 (5): 391-410
15. Plosker GL, Keating GM. Management of mild to moderate Alzheimer disease: defining the role of rivastigmine. Dis Manage Health Outcome 2004; 12 (1): 55-72
16. Novartis Europharm Limited. Product information (EU): Exelon® (rivastigmine tartarate) capsules and oral solution [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/exelon/exelon.htm [Accessed 2006 May 25]
17. Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. Acta Neurol Scand 1998 Apr; 97 (4): 244-50
18. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002; 59 (4): 563-72
19. Fogelson N, Kogan E, Korczyn AD, et al. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand 2003 Apr; 107 (4): 252-5
20. Ceravolo R, Volterrani D, Gambaccini G, et al. Acetylcholinesterase inhibitors in Parkinson's disease with dementia: a clinical and brain perfusional study [abstract no. S58.004]. Neurology 2004 Apr; 62 (7 Suppl. 5): A524
21. Novartis Pharmaceuticals Corporation. Product information (US): Exelon. (rivastigmine tartarate) capsules and oral solution [online]. Available from URL: http://www.fda.gov/cder [Accessed 2006 July 4]
22. Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet 2002; 41 (3): 225-34
23. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20 (4): 634-47
24. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 Dec 9; 351 (24): 2509-18
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washingon (DC): American Psychiatric Association, 1994
26. Tekin S, Lane R. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study. Prog Neurotherapeutics Neuropsychopharmacol 2005; 1 (1): 1-13
27. Wesnes KA, McKeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005 Nov 22; 65 (10): 1654-6
28. Burn D, Emre M, McKeith I, et al. Response to rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease (the EXPRESS study group) [poster]. 7th International Conference on Alzheimer's Disease and Parkinson's Disease; 2005 Mar 9-13; Sorrento
29. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006 Apr; 21 (4): 456-61
30. Willan AR, Goeree R, Pullenayegum EM, et al. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. Pharmacoeconomics 2006; 24 (1): 93-106
31. Ballard C, Lane R, Barone P, et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006 Jun; 60 (6): 639-45